TTI2

Summary

TTI2 (TELO2 interacting protein 2, HGNC:26262) is a protein-coding gene on chromosome 8p12, encoding TELO2-interacting protein 2 (Q6NXR4). Regulator of the DNA damage response (DDR). It is a selective cancer dependency (DepMap: 89.7% of cell lines).

This gene encodes a regulator of the DNA damage response. The protein is a component of the Triple T complex (TTT) which also includes telomere length regulation protein and TELO2 interacting protein 1. The TTT complex is involved in cellular resistance to DNA damage stresses and may act as a regulator of phosphoinositide-3-kinase-related protein kinase (PIKK) abundance.

Source: NCBI Gene 80185 — RefSeq curated summary.

At a glance

• Gene–disease (curated): severe intellectual disability-short stature-behavioral abnormalities-facial dysmorphism syndrome (Strong, GenCC)
• GWAS associations: 1
• Clinical variants (ClinVar): 127 total — 5 pathogenic, 2 likely-pathogenic
• Phenotypes (HPO): 35
• Druggable target: yes
• Cancer dependency (DepMap): dependent in 89.7% of screened cell lines
• MANE Select transcript: NM_001102401

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:26262
Approved symbol	TTI2
Name	TELO2 interacting protein 2
Location	8p12
Locus type	gene with protein product
Status	Approved
Aliases	FLJ23263
Ensembl gene	ENSG00000129696
Ensembl biotype	protein_coding
OMIM	614426
Entrez	80185

Gene structure

Transcript identifiers

Ensembl transcripts: 13 — 12 protein_coding, 1 protein_coding_CDS_not_defined

ENST00000360742, ENST00000431156, ENST00000519356, ENST00000520636, ENST00000523305, ENST00000613904, ENST00000897621, ENST00000897622, ENST00000897623, ENST00000929793, ENST00000929794, ENST00000929795, ENST00000954159

RefSeq mRNA: 4 — MANE Select: NM_001102401 NM_001102401, NM_001265581, NM_001330505, NM_025115

CCDS: CCDS6090, CCDS83276

Canonical transcript exons

ENST00000431156 — 8 exons

Exon	Start	End
ENSE00000911625	33509746	33509932
ENSE00001750909	33511967	33512712
ENSE00002092566	33513082	33513135
ENSE00002119909	33498722	33499277
ENSE00003468066	33500328	33500490
ENSE00003560309	33503429	33503572
ENSE00003637755	33507229	33507321
ENSE00003642953	33503748	33503935

Expression profiles

Bgee: expression breadth ubiquitous, 214 present calls, max score 83.69.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 10.1581 / max 240.9081, expressed in 1788 samples.

FANTOM5 promoters (2 alternative TSS)

Promoter ID	TPM avg	Samples expressed
92662	9.8991	1787
92661	0.2590	125

Top tissues by expression

277 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	83.69	gold quality
ventricular zone	UBERON:0003053	83.20	gold quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	82.46	gold quality
islet of Langerhans	UBERON:0000006	81.76	gold quality
ganglionic eminence	UBERON:0004023	81.25	gold quality
mucosa of transverse colon	UBERON:0004991	80.98	gold quality
cortical plate	UBERON:0005343	80.55	gold quality
stromal cell of endometrium	CL:0002255	80.54	gold quality
gastrocnemius	UBERON:0001388	80.22	gold quality
right testis	UBERON:0004534	80.08	gold quality
muscle of leg	UBERON:0001383	79.87	gold quality
left testis	UBERON:0004533	79.79	gold quality
testis	UBERON:0000473	79.67	gold quality
granulocyte	CL:0000094	79.63	gold quality
right adrenal gland	UBERON:0001233	79.20	gold quality
hindlimb stylopod muscle	UBERON:0004252	78.88	gold quality
leukocyte	CL:0000738	78.42	gold quality
monocyte	CL:0000576	78.28	gold quality
right adrenal gland cortex	UBERON:0035827	78.28	gold quality
left adrenal gland	UBERON:0001234	78.10	gold quality
mononuclear cell	CL:0000842	78.02	gold quality
blood	UBERON:0000178	77.94	gold quality
left adrenal gland cortex	UBERON:0035825	77.49	gold quality
thoracic aorta	UBERON:0001515	76.95	gold quality
heart left ventricle	UBERON:0002084	76.95	gold quality
ascending aorta	UBERON:0001496	76.92	gold quality
left coronary artery	UBERON:0001626	76.85	gold quality
apex of heart	UBERON:0002098	76.81	gold quality
descending thoracic aorta	UBERON:0002345	76.65	gold quality
calcaneal tendon	UBERON:0003701	76.65	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	8.11

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

45 targeting TTI2, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-4533	100.00	69.48	2758
HSA-MIR-4476	100.00	68.18	2030
HSA-MIR-6876-5P	100.00	67.68	2126
HSA-MIR-4795-3P	100.00	74.62	4024
HSA-MIR-1252-5P	100.00	69.80	2774
HSA-MIR-150-5P	99.99	66.69	1976
HSA-MIR-485-3P	99.98	70.68	1585
HSA-MIR-539-3P	99.98	70.74	1616
HSA-MIR-520D-5P	99.98	73.34	4883
HSA-MIR-524-5P	99.98	73.43	4882
HSA-MIR-5680	99.91	69.83	3421
HSA-MIR-3151-5P	99.86	63.83	1069
HSA-MIR-629-3P	99.85	67.99	1875
HSA-MIR-4799-5P	99.82	70.60	2663
HSA-MIR-6739-5P	99.80	67.87	2806
HSA-MIR-323A-3P	99.79	70.30	1739
HSA-MIR-4713-5P	99.78	67.80	1794
HSA-MIR-6733-5P	99.74	67.94	2759
HSA-MIR-4446-5P	99.72	69.19	2544
HSA-MIR-4755-5P	99.71	70.34	2716
HSA-MIR-5006-3P	99.71	70.26	2728
HSA-MIR-3059-5P	99.70	69.93	2491
HSA-MIR-7157-5P	99.66	69.33	1829
HSA-MIR-4310	99.59	68.84	2527
HSA-MIR-3153	99.55	67.59	2337
HSA-MIR-6833-5P	99.50	68.93	1161
HSA-MIR-143-3P	99.49	69.05	1457
HSA-MIR-4770	99.49	69.09	1451
HSA-MIR-365A-3P	99.43	70.02	836
HSA-MIR-365B-3P	99.43	70.02	836

Functional genomics

DepMap (CRISPR cell-line fitness): dependent in 89.7% of screened cell lines.

Literature-anchored findings (GeneRIF, showing 3)

• TTI1 and TTI2 protect cells from spontaneous DNA damage, and are required for the establishment of the intra-S and G2/M checkpoint. (PMID:20810650)
• The findings emphasises the role of the TTI2 gene in the etiology of intellectual disability. (PMID:23956177)
• Structure of the Human TELO2-TTI1-TTI2 Complex. (PMID:34838521)

Cross-species orthologs

3 orthologs

Organism	Symbol	Gene ID
danio_rerio	tti2	ENSDARG00000073773
mus_musculus	Tti2	ENSMUSG00000031577
rattus_norvegicus	Tti2	ENSRNOG00000023494

Protein

Protein identifiers

TELO2-interacting protein 2 — Q6NXR4 (reviewed: Q6NXR4)

All UniProt accessions (3): Q6NXR4, E5RHM7, E5RIH5

UniProt curated annotations — full annotation on UniProt →

Function. Regulator of the DNA damage response (DDR). Part of the TTT complex that is required to stabilize protein levels of the phosphatidylinositol 3-kinase-related protein kinase (PIKK) family proteins. The TTT complex is involved in the cellular resistance to DNA damage stresses, like ionizing radiation (IR), ultraviolet (UV) and mitomycin C (MMC). Together with the TTT complex and HSP90 may participate in the proper folding of newly synthesized PIKKs.

Subunit / interactions. Component of the TTT complex composed of TELO2, TTI1 and TTI2. Interacts with TELO2 and TTI1. Interacts with WAC; WAC positively regulates MTOR activity by promoting the assembly of the TTT complex and the RUVBL complex composed of RUVBL1 and RUVBL2 into the TTT-RUVBL complex which leads to the dimerization of the mTORC1 complex and its subsequent activation.

Disease relevance. Intellectual developmental disorder, autosomal recessive 39 (MRT39) [MIM:615541] A disorder characterized by significantly below average general intellectual functioning associated with impairments in adaptive behavior and manifested during the developmental period. MRT39 affected individuals show delayed psychomotor development, severe speech delay, short stature, kyphoscoliosis, and dysmorphic facial features. Behavioral abnormalities include hyperactivity, aggression, and stereotypic movements. The disease is caused by variants affecting the gene represented in this entry.

Similarity. Belongs to the TTI2 family.

RefSeq proteins (4): NP_001095871, NP_001252510, NP_001317434, NP_079391 (=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR016024	ARM-type_fold	Homologous_superfamily
IPR018870	Tti2	Family

Pfam: PF10521

UniProt features (6 total): sequence variant 3, chain 1, region of interest 1, sequence conflict 1

Structure

Experimental structures (PDB)

1 structures.

PDB	Method	Resolution (Å)
7OLE	ELECTRON MICROSCOPY	3.41

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q6NXR4-F1	84.85	0.59

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 255 (showing top): GOBP_REGULATION_OF_CELL_CYCLE_CHECKPOINT, GOBP_CELL_CYCLE_PHASE_TRANSITION, GRAESSMANN_APOPTOSIS_BY_DOXORUBICIN_DN, GRAESSMANN_RESPONSE_TO_MC_AND_DOXORUBICIN_DN, GOBP_NEGATIVE_REGULATION_OF_CELL_CYCLE_PROCESS, SHETH_LIVER_CANCER_VS_TXNIP_LOSS_PAM5, GOBP_NEGATIVE_REGULATION_OF_CELL_CYCLE, GOBP_PROTEIN_STABILIZATION, GOBP_REGULATION_OF_CELL_CYCLE, GOBP_REGULATION_OF_RESPONSE_TO_STRESS, GOBP_DNA_DAMAGE_RESPONSE, GOBP_REGULATION_OF_PROTEIN_STABILITY, GOBP_POSITIVE_REGULATION_OF_INTRACELLULAR_SIGNAL_TRANSDUCTION, GOBP_REGULATION_OF_DNA_DAMAGE_CHECKPOINT, GOBP_SIGNAL_TRANSDUCTION_IN_RESPONSE_TO_DNA_DAMAGE

GO Biological Process (2): protein stabilization (GO:0050821), positive regulation of DNA damage checkpoint (GO:2000003)

GO Molecular Function (0):

GO Cellular Component (2): nucleus (GO:0005634), TTT Hsp90 cochaperone complex (GO:0110078)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
regulation of protein stability	1
DNA damage checkpoint signaling	1
positive regulation of cell cycle checkpoint	1
regulation of DNA damage checkpoint	1
intracellular membrane-bounded organelle	1
protein-containing complex	1

Protein interactions and networks

STRING

1742 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
TTI2	TTI1	O43156	997
TTI2	TELO2	Q9Y4R8	990
TTI2	RUVBL1	P82276	758
TTI2	TRRAP	Q9Y4A5	684
TTI2	PIH1D1	Q9NWS0	644
TTI2	RPAP3	Q9H6T3	618
TTI2	HSP90AB1	P08238	618
TTI2	HSP90AA1	P07900	615
TTI2	RUVBL2	Q9Y230	581
TTI2	SMG1	Q96Q15	568
TTI2	ZNHIT2	Q9UHR6	453
TTI2	ATM	Q13315	423
TTI2	BTBD8	Q5XKL5	417
TTI2	MAK16	Q9BXY0	412
TTI2	ZNHIT3	Q15649	402

IntAct

62 interactions, top by confidence:

A	B	Type	Score
TELO2	TTI1	psi-mi:“MI:0915”(physical association)	0.760
TELO2	TTI1	psi-mi:“MI:0914”(association)	0.760
TTI2	TTI1	psi-mi:“MI:0914”(association)	0.690
GYPA	TCAF2	psi-mi:“MI:0914”(association)	0.640
TTI1	ATM	psi-mi:“MI:0914”(association)	0.610
APLNR	METTL15	psi-mi:“MI:0914”(association)	0.530
SLC39A9	B4GALT5	psi-mi:“MI:0914”(association)	0.530
NPTN	TNPO2	psi-mi:“MI:0914”(association)	0.530
BSG	BTAF1	psi-mi:“MI:0914”(association)	0.530
CMKLR1	SC5D	psi-mi:“MI:0914”(association)	0.530
LPAR1	TMEM223	psi-mi:“MI:0914”(association)	0.530
TTI2	OSBPL3	psi-mi:“MI:0915”(physical association)	0.400
	TUBA4A	psi-mi:“MI:0914”(association)	0.350
UNC93B1		psi-mi:“MI:0914”(association)	0.350
BSG	METTL15	psi-mi:“MI:0914”(association)	0.350
OPRM1	EXOC5	psi-mi:“MI:0914”(association)	0.350
TTI1	HSPA1A	psi-mi:“MI:0914”(association)	0.350
LDLRAD1	GXYLT2	psi-mi:“MI:0914”(association)	0.350
GPR17	TMEM120B	psi-mi:“MI:0914”(association)	0.350
TNFRSF10C	SLC22A23	psi-mi:“MI:0914”(association)	0.350
EFNA4	NBAS	psi-mi:“MI:0914”(association)	0.350
GYPA	HYKK	psi-mi:“MI:0914”(association)	0.350
GPRC5D	FAM234B	psi-mi:“MI:0914”(association)	0.350
CD80	POTEF	psi-mi:“MI:0914”(association)	0.350

BioGRID (86): TTI2 (Affinity Capture-MS), TELO2 (Affinity Capture-Western), TTI1 (Affinity Capture-Western), TTI2 (Affinity Capture-MS), TTI2 (Affinity Capture-MS), OSBPL3 (Affinity Capture-MS), TTI2 (Affinity Capture-MS), TTI2 (Affinity Capture-MS), TTI2 (Affinity Capture-MS), TTI2 (Affinity Capture-MS), TTI2 (Affinity Capture-MS), TTI2 (Affinity Capture-MS), OSBPL3 (Affinity Capture-MS), TTI2 (Affinity Capture-MS), TTI2 (Affinity Capture-MS)

ESM2 similar proteins: A0JMW6, A1L1L2, A1L2I9, A2A9C3, A4FV45, A8C756, B0I564, D3ZND0, E9Q2M9, G3HQ82, O15360, O35821, O70576, O75800, Q15021, Q1JPG0, Q24JP3, Q4KLN4, Q5T011, Q5U1Z0, Q5U249, Q66H56, Q6AXZ5, Q6GPP1, Q6NUQ4, Q6NXR4, Q6ZS81, Q7L4E1, Q8BGI5, Q8BK03, Q8BM55, Q8BMG7, Q8BTG3, Q8C3S2, Q8CJF7, Q8K2Z4, Q8K368, Q8WYP5, Q92574, Q99M76

Diamond homologs: Q66H56, Q6NXR4, Q8BGV4

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

127 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	5
Likely pathogenic	2
Uncertain significance	68
Likely benign	27
Benign	6

Top pathogenic / likely-pathogenic (7)

Variant ID	HGVS	Classification
2506446	NM_001102401.4(TTI2):c.539T>C (p.Leu180Pro)	Pathogenic
2506447	NM_001102401.4(TTI2):c.575T>C (p.Leu192Pro)	Pathogenic
4193429	NM_001102401.4(TTI2):c.693del (p.Ser230_Trp231insTer)	Pathogenic
858891	NM_001102401.4(TTI2):c.21_22insAAGCGCTCTG (p.Glu8fs)	Pathogenic
88867	NM_001102401.4(TTI2):c.1100C>T (p.Pro367Leu)	Pathogenic
3065604	NM_001102401.4(TTI2):c.1115+2T>C	Likely pathogenic
4845776	NM_001102401.4(TTI2):c.1115+1G>A	Likely pathogenic

SpliceAI

1859 predictions. Top by Δscore:

Variant	Effect	Δscore
8:33485222:G:GG	donor_gain	1.0000
8:33488372:TTGCA:T	acceptor_loss	1.0000
8:33488373:TGCA:T	acceptor_loss	1.0000
8:33488374:GCA:G	acceptor_loss	1.0000
8:33488375:CA:C	acceptor_loss	1.0000
8:33488376:AGGT:A	acceptor_loss	1.0000
8:33488377:GGTT:G	acceptor_gain	1.0000
8:33488428:G:GA	donor_loss	1.0000
8:33488513:A:AG	acceptor_gain	1.0000
8:33488514:T:G	acceptor_gain	1.0000
8:33488518:A:AG	acceptor_gain	1.0000
8:33488519:G:GT	acceptor_gain	1.0000
8:33488519:GA:G	acceptor_gain	1.0000
8:33488519:GAA:G	acceptor_gain	1.0000
8:33488519:GAAC:G	acceptor_gain	1.0000
8:33488519:GAACC:G	acceptor_gain	1.0000
8:33488625:GAAAG:G	donor_gain	1.0000
8:33488626:AAAGG:A	donor_loss	1.0000
8:33488627:AAGGT:A	donor_loss	1.0000
8:33488628:AG:A	donor_loss	1.0000
8:33488629:GGTA:G	donor_loss	1.0000
8:33488630:G:T	donor_loss	1.0000
8:33488631:T:A	donor_loss	1.0000
8:33488733:GGACA:G	acceptor_gain	1.0000
8:33489140:G:GG	donor_gain	1.0000
8:33495427:G:GT	donor_gain	1.0000
8:33495540:A:AC	acceptor_loss	1.0000
8:33495612:A:G	donor_gain	1.0000
8:33495617:G:GG	donor_gain	1.0000
8:33496614:AT:A	acceptor_gain	1.0000

AlphaMissense

3253 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
8:33503766:A:G	L366P	0.977
8:33503788:G:T	R359S	0.976
8:33503459:A:G	L410P	0.967
8:33509780:C:T	G267D	0.965
8:33500378:C:G	A458P	0.962
8:33503766:A:C	L366R	0.962
8:33500365:A:G	L462P	0.960
8:33509772:A:G	C270R	0.960
8:33509781:C:G	G267R	0.960
8:33503479:T:A	R403S	0.959
8:33503479:T:G	R403S	0.959
8:33507308:A:G	L283S	0.956
8:33503823:A:G	L347P	0.955
8:33509768:A:G	L271P	0.955
8:33503923:A:G	C314R	0.953
8:33503787:C:G	R359P	0.952
8:33509807:T:A	D258V	0.952
8:33503480:C:A	R403I	0.948
8:33512042:A:G	F191S	0.948
8:33500446:A:G	L435P	0.946
8:33503776:C:G	A363P	0.946
8:33503775:G:T	A363E	0.945
8:33509806:G:C	D258E	0.945
8:33509806:G:T	D258E	0.945
8:33503480:C:G	R403T	0.944
8:33503919:A:G	L315P	0.944
8:33503766:A:T	L366Q	0.943
8:33509770:A:C	C270W	0.941
8:33503513:A:G	L392P	0.940
8:33503835:A:G	L343P	0.940

dbSNP variants (sampled 300 via entrez): RS1000076670 (8:33508280 T>C), RS1000227776 (8:33510108 A>G), RS1000666036 (8:33509691 C>T), RS1001142133 (8:33510180 T>G), RS1001171051 (8:33504755 G>A), RS1001265923 (8:33504461 T>G), RS1001457198 (8:33502123 T>A), RS1001484175 (8:33514047 T>A,C), RS1001490144 (8:33498739 A>C), RS1001745145 (8:33511621 C>A), RS1002067000 (8:33511426 T>A), RS1002088952 (8:33513077 G>A), RS1002183343 (8:33506201 T>C), RS1002238228 (8:33506594 T>A,C), RS1002340675 (8:33500461 T>C)

Disease associations

OMIM: gene MIM:614426 | disease phenotypes: MIM:615541

GenCC curated gene-disease

Disease	Classification	Inheritance
severe intellectual disability-short stature-behavioral abnormalities-facial dysmorphism syndrome	Strong	Autosomal recessive

Mondo (2): severe intellectual disability-short stature-behavioral abnormalities-facial dysmorphism syndrome (MONDO:0014238), microcephaly (MONDO:0001149)

Orphanet (1): Severe intellectual disability-short stature-behavioral abnormalities-facial dysmorphism syndrome (Orphanet:391307)

HPO phenotypes

35 total (30 of 35 shown, HPO-id order):

HPO	Term
HP:0000007	Autosomal recessive inheritance
HP:0000164	Abnormality of the dentition
HP:0000233	Thin vermilion border
HP:0000252	Microcephaly
HP:0000340	Sloping forehead
HP:0000400	Macrotia
HP:0000448	Prominent nose
HP:0000486	Strabismus
HP:0000490	Deeply set eye
HP:0000664	Synophrys
HP:0000689	Dental malocclusion
HP:0000708	Atypical behavior
HP:0000718	Aggressive behavior
HP:0000733	Motor stereotypy
HP:0000737	Irritability
HP:0000750	Delayed speech and language development
HP:0000752	Hyperactivity
HP:0001263	Global developmental delay
HP:0001822	Hallux valgus
HP:0001888	Decreased total lymphocyte count
HP:0001999	Abnormal facial shape
HP:0002079	Hypoplasia of the corpus callosum
HP:0002342	Moderate intellectual disability
HP:0002360	Sleep disturbance
HP:0002486	Myotonia
HP:0002500	Abnormal cerebral white matter morphology
HP:0002650	Scoliosis
HP:0002751	Kyphoscoliosis
HP:0003593	Infantile onset
HP:0004322	Short stature

GWAS associations

1 associations (top):

Study	Trait	p-value
GCST006626_14	Pulse pressure	1.000000e-09

EFO canonical traits (1, from GWAS)

EFO ID	Trait name
EFO:0005763	pulse pressure measurement

MeSH disease descriptors (1)

Descriptor	Name	Tree numbers
D008831	Microcephaly	C05.660.207.620; C10.500.507.400.500; C16.131.621.207.620; C16.131.666.507.400.500

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (1): CHEMBL6067131 (SINGLE PROTEIN)

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

14 total (human), top 14 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
bisphenol A	increases abundance, affects cotreatment, decreases methylation, affects expression	2
ginger extract	affects cotreatment, affects expression, increases abundance	1
sodium arsenite	affects expression	1
di-n-butylphosphoric acid	affects expression	1
Fulvestrant	decreases methylation, affects cotreatment	1
Air Pollutants	decreases expression, increases abundance	1
Benzo(a)pyrene	increases methylation	1
Doxorubicin	affects expression	1
Oils, Volatile	affects expression, increases abundance, affects cotreatment	1
Phthalic Acids	increases methylation	1
Valproic Acid	increases expression	1
7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide	decreases expression	1
Lactic Acid	decreases expression	1
Particulate Matter	decreases expression, increases abundance	1

ChEMBL screening assays

1 unique, capped per target: 1 binding

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL5652712	Binding	Binding affinity to human TTI2 incubated for 45 mins by Kinobead based pull down assay	NVP-BHG712: Effects of Regioisomers on the Affinity and Selectivity toward the EPHrin Family. — ChemMedChem

Clinical trials (associated diseases)

17 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT05518188	PHASE1/PHASE2	RECRUITING	Melpida: Recombinant Adeno-associated Virus (serotype 9) Encoding a Codon Optimized Human AP4M1 Transgene (hAP4M1opt)
NCT00001639	Not specified	COMPLETED	Evaluation of Patients With Unresolved Chromosome Abnormalities
NCT01151462	Not specified	WITHDRAWN	Postnatal HCMV Infection in Very Preterm Infants. Implications, Morbidity, Growth and Neurodevelopmental Outcomes.
NCT01565005	Not specified	COMPLETED	Microcephaly Genetic Deficiency in Neural Progenitors
NCT02510170	Not specified	COMPLETED	Fetal and Maternal Head Circumference During Pregnancy in Israeli Population
NCT02741882	Not specified	COMPLETED	Zika and Microcephaly: Case-control Study
NCT02943304	Not specified	COMPLETED	Neurodevelopment Outcome of Newborns Exposed to Zika Virus (ZIKV) in Utero
NCT03255369	Not specified	UNKNOWN	Vertical Exposure to Zika Virus and Its Consequences for Child Neurodevelopment (ZIKVIRUSIFF)
NCT03325946	Not specified	RECRUITING	The FBRI VTC Neuromotor Research Clinic
NCT03330600	Not specified	COMPLETED	Efficacy of Aquatic Physiotherapy in Children With Microcephaly by Zika Virus Congenital Syndrome
NCT03548779	Not specified	COMPLETED	North Carolina Genomic Evaluation by Next-generation Exome Sequencing, 2
NCT03651687	Not specified	COMPLETED	Guangzhou Surveillance and Clinical Study in Microcephaly (GSCSM)
NCT03922594	Not specified	TERMINATED	Surveillance of Zika-related Microcephaly in Sub-Saharan Africa and Asia
NCT04816175	Not specified	COMPLETED	Intensive Therapy for Children With Microcephaly, Hyperkinetic Movements, or Global Developmental Delay
NCT05322980	Not specified	COMPLETED	Summary of Infants Weighing 500 Grams or Less
NCT06019182	Not specified	RECRUITING	MEHMO Natural History and Biomarkers
NCT06566066	Not specified	RECRUITING	Register for Patients With Thyroid Hormone Resistance.